Home ETF List About

Portfolio Holdings Detail for ISIN IE0031442068
Stock Name / FundiShares Core S&P 500 UCITS ETF USD (Dist)
IssuerBlackrock
Entity holding fund iShares Public Limited Company
Entity TypeUmbrella investment company with variable capital and having segregated liability between its funds
Entity LEI 549300YDM1GFZR5B4U80
ETF TickerIDUS(USD) LSE
ETF TickerIDUS.LS(USD) CXE
ETF TickerIUSA.AS(EUR) CXE
ETF TickerIUSA.DE(EUR) CXE
ETF TickerIUSA.LS(GBX) CXE
ETF TickerIUSA.MI(EUR) CXE
ETF TickerIUSAz(USD) CXE
ETF TickerIUSA(EUR) ETF Plus
ETF TickerIDUS.L(GBP) LSE

Holdings detail for REGN

Stock NameRegeneron Pharmaceuticals Inc
TickerREGN(USD) NASDAQ
TYPECommon Stock
CountryUSA
ISINUS75886F1075
LEI549300RCBFWIRX3HYQ56

Show aggregate REGN holdings

News associated with REGN

Regeneron And Sanofi : CHMP Recommends EU Approval Of Dupixent For Chronic Spontaneous Urticaria
(RTTNews) - Regeneron Pharmaceuticals Inc. (REGN) and Sanofi announced that the European Medicines Agency's Committee for Medicinal Products for Human Use or CHMP has adopted a positive opinion recommending the approval of Dupixent (dupilumab) in the European Union for treating c - 2025-09-22 02:12:20
Peek Under The Hood: JEPQ Has 10% Upside
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-09-08 08:26:56
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Given Consensus Rating of “Moderate Buy” by Brokerages
Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Get Free Report) have been given an average recommendation of “Moderate Buy” by the twenty-six analysts that are currently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell rating, six have issued a hold rating, sixteen have assigned a buy rating and three […] - 2025-08-26 02:16:48
LABU, INCY, UTHR, REGN: ETF Outflow Alert
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Direxion Daily S&P Biotech Bull 3x Shares (Symbol: LABU) where we have detected an approximate $67.3 million dollar outflow -- that's a 9.4% dec - 2025-08-20 12:04:03
Regeneron Pharmaceuticals (NASDAQ:REGN) versus Cadrenal Therapeutics (NASDAQ:CVKD) Head-To-Head Analysis
Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) and Cadrenal Therapeutics (NASDAQ:CVKD – Get Free Report) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, analyst recommendations, valuation, institutional ownership, profitability and earnings. Volatility and Risk Regeneron Pharmaceuticals has a beta […] - 2025-08-20 02:22:48
Truist Financial Cuts Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target to $812.00
Regeneron Pharmaceuticals (NASDAQ:REGN – Free Report) had its price target reduced by Truist Financial from $940.00 to $812.00 in a research note published on Monday,Benzinga reports. They currently have a buy rating on the biopharmaceutical company’s stock. REGN has been the topic of several other reports. The Goldman Sachs Group dropped their price target on […] - 2025-08-14 03:00:52
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock Position Raised by Blair William & Co. IL
Blair William & Co. IL lifted its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 2.2% in the 1st quarter, Holdings Channel reports. The fund owned 1,282 shares of the biopharmaceutical company’s stock after buying an additional 27 shares during the period. Blair William & Co. IL’s holdings in Regeneron Pharmaceuticals were worth […] - 2025-08-11 06:26:50
Harbour Investments Inc. Sells 32 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
Harbour Investments Inc. reduced its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 7.4% in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 403 shares of the biopharmaceutical company’s stock after selling 32 shares during the quarter. Harbour Investments Inc.’s holdings in […] - 2025-08-07 09:40:47
We Did The Math SPYX Can Go To $58
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-08-07 08:58:54
409 Shares in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Purchased by Arkadios Wealth Advisors
Arkadios Wealth Advisors purchased a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 409 shares of the biopharmaceutical company’s stock, valued at approximately $259,000. Several other institutional investors and hedge funds also […] - 2025-08-07 05:38:53
Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price Expected to Rise, BMO Capital Markets Analyst Says
Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) had its price target upped by stock analysts at BMO Capital Markets from $600.00 to $640.00 in a research report issued on Monday,Benzinga reports. The firm currently has an “outperform” rating on the biopharmaceutical company’s stock. BMO Capital Markets’ price target indicates a potential upside of 12.30% from […] - 2025-08-06 03:12:48
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Receives $828.86 Consensus Target Price from Brokerages
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Get Free Report) has been given a consensus rating of “Moderate Buy” by the twenty-four ratings firms that are currently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, six have issued a hold recommendation, fifteen have assigned a buy recommendation and two […] - 2025-08-04 02:59:01
Stocks Slump on Tariffs and Weak US Job Growth
The S&P 500 Index ($SPX ) (SPY ) today is down -1.70%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -1.48%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -2.01%. September E-mini S&P futures (ESU25 ) are down -1.75%, and September E-mini Nasdaq futures... - 2025-08-01 19:31:54
Stocks Slump on Tariffs and Weak US Job Growth
The S&P 500 Index ($SPX ) (SPY ) today is down -1.70%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -1.48%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -2.01%. September E-mini S&P futures (ESU25 ) are down -1.75%, and September E-mini Nasdaq futures... - 2025-08-01 14:40:40
Stocks Slump on Tariffs and Weak US Job Growth
The S&P 500 Index ($SPX ) (SPY ) today is down -1.70%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -1.48%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -2.01%. September E-mini S&P futures (ESU25 ) are down -1.75%, and September E-mini Nasdaq futures... - 2025-08-01 14:35:36
Stocks Slump on Tariffs and Weak US Job Growth
The S&P 500 Index ($SPX ) (SPY ) today is down -1.70%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -1.48%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -2.01%. September E-mini S&P futures (ESU25 ) are down -1.75%, and September E-mini Nasdaq futures... - 2025-08-01 14:02:25
Nasdaq 100 Movers: MRVL, REGN
In early trading on Friday, shares of Regeneron Pharmaceuticals, topped the list of the day's best performing components of the Nasdaq 100 index, trading up 3.6%. Year to date, Regeneron Pharmaceuticals, has lost about 20.7% of its value. And the worst performing Nasdaq 100 co - 2025-08-01 11:30:09
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Purchased by Choreo LLC
Choreo LLC boosted its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 0.9% during the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 3,746 shares of the biopharmaceutical company’s stock after acquiring an additional 32 shares during the period. Choreo LLC’s holdings in Regeneron Pharmaceuticals […] - 2025-07-24 07:22:56
Crestwood Advisors Group LLC Grows Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
Crestwood Advisors Group LLC increased its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 5.7% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 467 shares of the biopharmaceutical company’s stock after purchasing an additional 25 shares during the quarter. Crestwood Advisors Group […] - 2025-07-24 05:47:12
Kestra Private Wealth Services LLC Has $1.31 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
Kestra Private Wealth Services LLC grew its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 6.9% in the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 2,058 shares of the biopharmaceutical company’s stock after buying an additional 132 shares during the quarter. […] - 2025-07-23 07:50:58
Larson Financial Group LLC Has $34,000 Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
Larson Financial Group LLC lessened its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 34.6% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 53 shares of the biopharmaceutical company’s stock after selling 28 shares during the quarter. Larson […] - 2025-07-23 06:30:53
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Purchased by Alps Advisors Inc.
Alps Advisors Inc. raised its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 71.0% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 530 shares of the biopharmaceutical company’s stock after purchasing an additional 220 shares during the quarter. Alps Advisors Inc.’s […] - 2025-07-17 05:50:54
Stratos Wealth Partners LTD. Sells 115 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
Stratos Wealth Partners LTD. trimmed its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 18.5% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 506 shares of the biopharmaceutical company’s stock after selling 115 shares during the period. Stratos Wealth Partners […] - 2025-07-16 04:58:54
Allworth Financial LP Reduces Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
Allworth Financial LP trimmed its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 14.3% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 821 shares of the biopharmaceutical company’s stock after selling 137 shares during the period. Allworth Financial […] - 2025-07-15 08:20:00
Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Raised to $584.00
Regeneron Pharmaceuticals (NASDAQ:REGN – Free Report) had its price target increased by UBS Group from $560.00 to $584.00 in a report issued on Friday,Benzinga reports. The brokerage currently has a neutral rating on the biopharmaceutical company’s stock. Several other research analysts also recently commented on REGN. BMO Capital Markets reduced their price objective on Regeneron […] - 2025-07-14 03:30:48
Brown Advisory Inc. Reduces Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
Brown Advisory Inc. lowered its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 5.5% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 4,269 shares of the biopharmaceutical company’s stock after selling 247 shares during the quarter. Brown Advisory Inc.’s […] - 2025-07-13 05:54:54
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock Holdings Cut by D.A. Davidson & CO.
D.A. Davidson & CO. reduced its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 2.8% in the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 732 shares of the biopharmaceutical company’s stock after selling 21 shares during the quarter. D.A. […] - 2025-07-11 05:32:52
Brokerages Set Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) PT at $813.57
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Get Free Report) has received an average recommendation of “Moderate Buy” from the twenty-five ratings firms that are covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell rating, six have issued a hold rating, fifteen have assigned a buy rating and three have issued […] - 2025-07-10 03:07:00
DAVENPORT & Co LLC Makes New Investment in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
DAVENPORT & Co LLC purchased a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 427 shares of the biopharmaceutical company’s stock, valued at approximately $271,000. A number of other institutional […] - 2025-07-09 05:11:22
Bessemer Group Inc. Sells 3,860 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
Bessemer Group Inc. decreased its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 76.0% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,218 shares of the biopharmaceutical company’s stock after selling 3,860 shares during the period. Bessemer Group […] - 2025-07-01 05:46:52

iShares Core S&P 500 UCITS ETF USD (Dist) REGN holdings

DateNumber of REGN Shares HeldBase Market Value of REGN SharesLocal Market Value of REGN SharesChange in REGN Shares HeldChange in REGN Base ValueCurrent Price per REGN Share HeldPrevious Price per REGN Share Held
2025-09-29 (Monday)36,102USD 20,244,197REGN holding decreased by -113721USD 20,244,1970USD -113,721 USD 560.75 USD 563.9
2025-09-26 (Friday)36,102USD 20,357,918REGN holding increased by 302896USD 20,357,9180USD 302,896 USD 563.9 USD 555.51
2025-09-25 (Thursday)36,102REGN holding increased by 14USD 20,055,022REGN holding decreased by -767032USD 20,055,02214USD -767,032 USD 555.51 USD 576.98
2025-09-24 (Wednesday)36,088REGN holding decreased by -848USD 20,822,054REGN holding decreased by -1291899USD 20,822,054-848USD -1,291,899 USD 576.98 USD 598.71
2025-09-18 (Thursday)36,936REGN holding increased by 14USD 22,113,953REGN holding increased by 496122USD 22,113,95314USD 496,122 USD 598.71 USD 585.5
2025-09-17 (Wednesday)36,922REGN holding increased by 14USD 21,617,831REGN holding increased by 393517USD 21,617,83114USD 393,517 USD 585.5 USD 575.06
2025-09-16 (Tuesday)36,908USD 21,224,314REGN holding increased by 91162USD 21,224,3140USD 91,162 USD 575.06 USD 572.59
2025-09-15 (Monday)36,908USD 21,133,152USD 21,133,152
2025-09-12 (Friday)36,908USD 20,668,480USD 20,668,480
Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of REGN by Blackrock for IE0031442068

Show aggregate share trades of REGN

DateActionQuantityMarket HighMarket LowLikely Trade PriceLikely Trade Value (Profit/Loss)Average Price previous trades
2025-09-25BUY14 555.510* 650.43
2025-09-24SELL-848 576.980* 650.79 Profit of 551,872 on sale
2025-09-18BUY14 598.710* 651.05
2025-09-17BUY14 585.500* 651.38
2025-08-19SELL-28 571.780* 652.74 Profit of 18,277 on sale
2025-08-15SELL-14 580.410* 653.52 Profit of 9,149 on sale
2025-08-13SELL-70 561.550* 653.99 Profit of 45,780 on sale
2025-08-12SELL-182 556.555* 654.50 Profit of 119,119 on sale
2025-08-07SELL-210 559.800* 654.99 Profit of 137,548 on sale
2025-08-05BUY14 569.900* 655.97
2025-07-31BUY42 545.460* 656.55
2025-07-28BUY14 558.630* 658.15
2025-07-25SELL-28 563.100* 658.67 Profit of 18,443 on sale
2025-07-24BUY14 564.640* 659.18
2025-07-18BUY14 542.520* 661.49
2025-07-14SELL-14 570.590* 663.93 Profit of 9,295 on sale
2025-07-08SELL-28 547.750* 665.84 Profit of 18,644 on sale
2025-07-02BUY84 547.740* 668.70
2025-06-24SELL-28 522.270* 673.18 Profit of 18,849 on sale
2025-06-23SELL-14 511.920* 674.17 Profit of 9,438 on sale
2025-06-20SELL-473 509.720* 675.18 Profit of 319,360 on sale
2025-06-12SELL-42 521.840* 679.25 Profit of 28,528 on sale
2025-06-06BUY14 493.220* 683.56
2025-06-02SELL-42 490.810* 688.81 Profit of 28,930 on sale
2025-05-29SELL-14 605.390* 690.72 Profit of 9,670 on sale
2025-05-27BUY14 603.260* 691.99
2025-05-23BUY14 588.340* 693.43
2025-05-21SELL-42 604.620* 694.74 Profit of 29,179 on sale
2025-05-15BUY56 584.990* 697.55
2025-05-14SELL-84 571.360* 698.47 Profit of 58,672 on sale
2025-05-13SELL-168 574.160* 699.39 Profit of 117,497 on sale
2025-05-07SELL-42 560.930* 703.82 Profit of 29,561 on sale
2025-05-02SELL-14 605.610* 706.49 Profit of 9,891 on sale
2025-04-29SELL-42 568.910* 709.36 Profit of 29,793 on sale
2025-04-24BUY14 599.760* 711.92
2025-04-22BUY56 585.490* 713.99
2025-04-16BUY14 549.280* 719.28
2025-04-15BUY14 557.910* 720.67
2025-04-11BUY28 554.180* 723.44
2025-04-09BUY70 576.720* 726.33
2025-04-08BUY210 556.810* 727.86
2025-04-07SELL-98 572.780* 729.27 Profit of 71,468 on sale
2025-04-04SELL-210 573.450* 730.70 Profit of 153,447 on sale
2025-04-02SELL-42 625.600* 731.67 Profit of 30,730 on sale
2025-04-01SELL-14 617.000* 732.74 Profit of 10,258 on sale
2025-03-31SELL-28 634.230* 733.67 Profit of 20,543 on sale
2025-03-28BUY28 637.360* 734.59
2025-03-25BUY42 634.140* 737.47
2025-03-24BUY56 661.000* 738.23
2025-03-21SELL-28 658.480* 739.02 Profit of 20,693 on sale
2025-03-20BUY28 662.620* 739.80
2025-03-19BUY56 672.360* 740.48
2025-03-17SELL-42 678.420* 741.92 Profit of 31,161 on sale
2025-03-14SELL-28 666.870* 742.71 Profit of 20,796 on sale
2025-03-13SELL-84 680.610* 743.37 Profit of 62,443 on sale
2025-03-12SELL-121 689.500* 743.95 Profit of 90,018 on sale
2025-03-11SELL-98 718.160* 744.23 Profit of 72,934 on sale
2025-03-10SELL-56 744.830* 744.22 Profit of 41,676 on sale
2025-03-06SELL-56 698.440* 745.15 Profit of 41,728 on sale
2025-03-05SELL-84 687.150* 745.81 Profit of 62,648 on sale
2025-03-04SELL-112 675.490* 746.62 Profit of 83,621 on sale
2025-02-28SELL-70 698.740* 747.91 Profit of 52,353 on sale
2025-02-26BUY28 706.940* 748.94
2025-02-24BUY28 713.250* 749.70
2025-02-21BUY14 700.330* 750.31
2025-02-20SELL-42 696.020* 751.00 Profit of 31,542 on sale
2025-02-14SELL-14 673.600* 754.88 Profit of 10,568 on sale
2025-02-13SELL-182 674.270* 755.97 Profit of 137,587 on sale
2025-02-12SELL-14 663.860* 757.24 Profit of 10,601 on sale
2025-02-06SELL-56 722.070* 760.73 Profit of 42,601 on sale
2025-02-05BUY14 716.720* 761.38
2025-02-04BUY98 697.050* 762.34
2025-01-29SELL-98 687.270* 767.72 Profit of 75,237 on sale
2025-01-28BUY28 686.330* 769.03
2025-01-24BUY14 675.790* 771.99
2025-01-22BUY28 680.030* 774.91
2025-01-16BUY28 693.230* 781.49
2025-01-15BUY14 703.430* 782.97
2025-01-10BUY28 696.880* 787.85
2025-01-02BUY42 715.190* 791.71
2024-12-31BUY28 712.330* 793.43
2024-12-27BUY14 712.400* 797.34
2024-12-20SELL-340 701.850* 805.87 Profit of 273,995 on sale
2024-12-19BUY14 708.250* 808.37
2024-12-18SELL-14 714.620* 810.84 Profit of 11,352 on sale
2024-12-17BUY28 740.010* 812.75
2024-12-13BUY14 731.300* 817.59
2024-12-10BUY14 778.500* 820.13
2024-12-06SELL-28 778.000* 822.52 Profit of 23,031 on sale
2024-12-05BUY14 767.900* 824.34
2024-12-04SELL-112 754.260* 826.76 Profit of 92,597 on sale
2024-12-03BUY42 749.570* 829.52
2024-12-02BUY70 762.340* 832.00
2024-11-27BUY14 754.870* 841.84
2024-11-26BUY98 753.030* 845.70
2024-11-21BUY42 744.500* 860.96
2024-11-20BUY28 743.350* 867.15
2024-11-19BUY14 744.600* 873.95
2024-11-18BUY28 762.000* 880.54
2024-11-12BUY56 821.000* 884.26
2024-11-11BUY28 825.680* 888.17
2024-11-08BUY112 828.420* 892.43
2024-11-07BUY98 824.480* 897.66
2024-11-06BUY112 816.650* 904.41
2024-11-05SELL-28 829.430* 911.23 Profit of 25,514 on sale
2024-11-04BUY28 828.840* 919.47
2024-11-01BUY98 843.600* 927.90
2024-10-28BUY70 928.610* 946.83
2024-10-25BUY154 933.020* 950.28
2024-10-23SELL-14 941.390* 965.42 Profit of 13,516 on sale
2024-10-21BUY14 968.500* 0.00
Market high and low price is on the date.

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of REGN

DateShorted VolumeShort Exempt VolumeTotal Shares Traded% Shorted
2025-09-19208,6591,635312,81266.7%
2025-09-18236,4853,679387,51961.0%
2025-09-17229,191716370,89561.8%
2025-09-16173,632584271,02064.1%
2025-09-15204,491251334,49661.1%
2025-09-12117,50433222,76052.7%
2025-09-11125,4783,137286,51643.8%
2025-09-10195,068481339,88557.4%
2025-09-09129,168994274,52047.1%
2025-09-08250,895396527,06247.6%
2025-09-05170,149290289,56658.8%
2025-09-04188,2272,103360,61952.2%
2025-09-03185,679344438,11142.4%
2025-09-02191,954138476,28840.3%
2025-08-29133,226685236,72656.3%
2025-08-28116,5602,177256,67545.4%
2025-08-27113,719465243,83646.6%
2025-08-26210,376450400,19952.6%
2025-08-25149,13068363,37741.0%
2025-08-22211,8223,244701,77030.2%
2025-08-21257,4923,416446,43957.7%
2025-08-20327,738572559,13358.6%
2025-08-19118,4722,191324,31136.5%
2025-08-18146,282388277,90952.6%
2025-08-15209,9233,375441,75247.5%
2025-08-14157,5693,623429,32736.7%
2025-08-13111,342233362,78630.7%
2025-08-12117,647171310,77537.9%
2025-08-11129,5132,676284,75745.5%
2025-08-08128,5591,038431,84129.8%
2025-08-07166,6481,560352,87747.2%
2025-08-06176,311624397,08944.4%
2025-08-05154,257115353,74443.6%
2025-08-04200,7581,913409,89749.0%
2025-08-01349,7753,745728,72048.0%
2025-07-31222,350476549,34440.5%
2025-07-30106,8391,689231,76146.1%
2025-07-29149,359276292,66751.0%
2025-07-28103,6871,380245,28742.3%
2025-07-25103,783556259,06940.1%
2025-07-24156,9742,397291,67753.8%
2025-07-23168,7341,708355,37247.5%
2025-07-22116,324617304,88038.2%
2025-07-2198,482900250,10739.4%
2025-07-18183,1741,051391,90946.7%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.